Botox might be used as a migraine headache treatment in the future, according to new research published by physicians. In a recent study published in the medical journal Archives of Dermatology, doctors basically recommend the alternative use of Botox Cosmetic as a migraine treatment, saying that Botox injections “at dosesappropriate for cosmetic purposes may be sufficient to preventmigraine attacks.”
According to writers on Bloomberg news, pharmaceutical company and Botox manufacturer Allergan applied for FDA clearance to market Botox as a headache treatment. However, researchers say they cannot fully explain how Botox works to relieve headaches. One co-author of the study, Rami Burstein says, “it may block the signals in sensory nerves located on the outside of the head.”
The FDA just granted clearance last week to a new wrinkle filler called Juvederm Ultra XC – prepared in advance with 0.3 % lidocaine.
In the company press release (and on Juvederm.com) the manufacturer cites results of a clinical trial demonstrating a significant improvement in comfort with the new filler: over 90 percent of 72 subjects in the trial said they experienced less pain with Juvederm XC.
Don’t expect physicians to abandon existing methods of pain management, but they may use the new filler within a comprehensive treatment plan for comfortable dermal filler injection. We’ll know more about Juvederm XC if/when it is available in Maple Valley.
Every day, our bodies naturally produce evidence of what we consume. However, the process is much more complicated than the old adage “you are what you eat.” Research shows that a cell-level battle is raging within each of us — a battle between the natural process of aging and the natural systems that help us resist that very process.
For instance, let’s look at oxygen. Oxygen is everywhere; it is in the air we breathe, the water we drink, and in the food we eat and unfortunately, oxygen has a natural tendency to combine with cellular processes in our skin to produce free radicals. Once produced, these agents become the enemy of our skin tissue. Much like the effects of oxygen on metal, which causes oxidation and eventually rust, our bodies experience inflammation, and this inflammation can take many forms. On the skin, inflammation can make your pores look bigger and complexion look duller. Discoloration, wrinkles, acne, and even eczema are also related to the damaging effects of oxidation-related inflammation.
What can we do? Well, consider the fact that Vitamins A, C, and E are “antioxidant rich” adversaries of the free radicals that hide in our cells and attack our skin. Consider that Selenium is a mineral that experts agree is critical to the production of glutathione, another enemy of free radicals. Consider that Thiamine is a B vitamin that helps skin cells function normally. Consider that Zinc assists epidermal cell growth, that protein is essential for skin repair, and finally, that Vitamin C helps the body naturally manufacture collagen, a protein that keeps the skin supple and tight. The truth is, research shows that vitamins and minerals are essential to skin health because they maintain a system of resistance to the processes commonly associated with aging, and those vitamins and minerals reside in the foods we eat.
The anti-aging/skin care industry has always been competitive, but this battle for market share has been escalating recently and now the competition between makers of medical grade skin care products has taken an interesting turn. ZO Skin Health just filed suit against Obagi Medical Products (OMP), both companies being founded by the same leader in the industry, Dr. Zein Obagi.
According to the complaint filed in the Superior Court of California, County of Los Angeles, OMP allegedly interfered with the distribution of Dr. Obagi’s new line of anti-aging products that he developed for his current company, ZO Skin Health. Reports say the disagreement likely stems from a non-compete agreement between the two parties, and whether that agreement should stop ZO Skin Health from distributing its new line of anti-aging products directly to consumers over the internet. OMP denies any wrongful conduct in the matter, and says it will vigorously defend the suit.
As the demand for anti-aging skin care products has increased over the last decade, so has the competition within that market. Between 2006 and 2008, U.S. sales alone rose 13% to 1.6 billion dollars, and the trend shows no sign of weakening as baby-boomers take advantage of advances in skin care science to address the effects of aging on their appearance.
The Grossman Burn Foundation, the philanthropic arm of the Grossman Burn Center, has this week announced that Solta Medical Inc. has donated a Fraxel re:store laser system to the Burn Center, offering immediate benefits to Burn Center patients.
The Fraxel system will be used to reduce the appearance of scarring caused by traumatic thermal damage. The Burn Center is a worldwide leader in innovative treatment and care for burn patients and their families.
In making the donation, the Chairman of the Board, President and CEO of Solta Medical, Inc., Stephen J. Fanning, applauded the Grossman Burn Foundation’s efforts to provide highly-skilled non-profit reconstructive surgery to treat patients’ scars and help their recovery, adding that “The Grossman Burn Foundation is well known for their humanitarian efforts to assist burn victims and their families throughout the world…”
And it’s true. The Grossman Burn Foundation provides burn care and medical resources in developing countries all over the globe, including a burn center in Kabul and a physician triage training program for doctors in underdeveloped countries. The Foundation is also involved in the development and distribution of satellite based telemedicine equipment to doctors and first responders all over the globe. The donation of the Fraxel system, therefore, was a natural fit for Solta Medical, a world leader in the laser skin resurfacing technology.
“The goal of restorative burn care is to return the patient to as close to pre-injury status as possible…” said Rebecca Grossman, the Chair of the Grossman Burn Foundation. “We plan to use the cutting-edge Fraxel technology to restore our burn-injured patients and play a key role in providing better and faster patient outcomes.”
A: Latisse is a bimatoprost ophthalmic solution 0.03%, originally developed and used as a glaucoma medication. In using the medication, many patients noticed that their eyelashes grew. Some even had to trim their lashes due to excessive length. Allergan, who owned the medication, began to market it as Latisse, for topical use in patients with “inadequate eyelashes.”
Q: How long has Latisse been on the market?
A: Although Latisse has been available for just over 6 months, its related safety record as an eye drop solution, spans well over 10 years. Any medication that is used in the eye must be very safe.
Q: Why do I need a prescription for Latisse?
A: Latisse can result in eyelash improvement of 105% in thickness and over 25% in length. Latisse is not an over-the-counter medication. The FDA approved Latisse as a prescription medication to treat hypotrichosis, i.e. reduced amount of eyelash growth.
Beauty may be more than skin-deep after all. According to new research, your appearance may actually be an accurate indicator of your health and potential for survival.
The study: “Perceived age as clinically useful biomarker of ageing: cohort study” was recently published in the British Medical Journal.
Danish researchers measured the perceived age of twins and found that perceived age was correlated with survival; i.e. the younger looking twin was likely to live longer than his or her twin counterpart. Researchers also found significant correlations between perceived age and healthy functioning – both cognitive and physical.
Ultra XC – prepared in advance with 0.3 % lidocaine.
process is much more complicated than the old adage “you are what you eat.” Research shows that a cell-level battle is raging within each of us — a battle between the natural process of aging and the natural systems that help us resist that very process.
market share has been escalating recently and now the competition between makers of medical grade skin care products has taken an interesting turn. ZO Skin Health just filed suit against 
many patients noticed that their eyelashes grew. Some even had to trim their lashes due to excessive length. Allergan, who owned the medication, began to market it as Latisse, for topical use in patients with “inadequate eyelashes.”
appearance may actually be an accurate indicator of your health and potential for survival.
